Clinical Research Directory
Browse clinical research sites, groups, and studies.
SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma
Sponsor: Fujian Cancer Hospital
Summary
To investigate the objective response rate (ORR) of stereotactic body radiotherapy (SBRT) combined with anlotinib and beromuzumab in locally advanced/metastatic renal cell carcinoma.
Official title: A Phase II Multicenter Study of Stereotactic Body Radiation Therapy (SBRT) Combined With Anlotinib and Bimepolizumab in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
27
Start Date
2027-02-01
Completion Date
2029-06-01
Last Updated
2026-03-24
Healthy Volunteers
No
Interventions
Stereotactic Body Radiation Therapy (SBRT)
Dose fractionation: 39-48Gy/3f or 40-50Gy/5f, alternative 20-50Gy/5f if OAR dose-limited. Dose adjusted per radiation toxicities during treatment.
Anlotinib
Oral anti-angiogenic agent, 12 mg qd fasting, 21d/cycle (2w on/1w off)
Bemarituzumab
Intravenous PD-1 inhibitor, 1200 mg q3w, 60min infusion
Locations (1)
Fujian Cancer Hospital
Fuzhou, Fujian, China